Lv5
1070 积分 2022-07-16 加入
Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization
5天前
已完结
Sintilimab and lenvatinib plus hepatic arterial infusion chemotherapy and embolization as conversion therapy for uHCC: A phase 2 trial
18天前
已完结
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
19天前
已完结
Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival
1个月前
已完结
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
1个月前
已完结
Establishing hepatic decompensation as a meaningful clinicaloutcome during systemic therapy for hepatocellular carcinoma
2个月前
已完结
Establishing hepatic decompensation as a meaningful clinicaloutcome during systemic therapy for hepatocellular carcinoma
2个月前
已完结
Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study
2个月前
已完结
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
2个月前
已完结
Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review
2个月前
已完结
皖公网安备34019202002308
